Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2028

Conditions

Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma

Interventions

DRUG

QLS31905 for Injection

DRUG

QL2107 Injection

DRUG

Oxaliplatin Injection

DRUG

Capecitabine Tablets

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY